Advertisement

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

Anas Younes, Yasuhiro Oki, Peter McLaughlin, Amanda R. Copeland, Andre Goy, Barbara Pro, Lei Feng, Ying Yuan, Hubert H. Chuang, Homer A. Macapinlac, Fredrick Hagemeister, Jorge Romaguera, Felipe Samaniego, Michelle A. Fanale, Bouthaina Shbib Dabaja, Maria A. Rodriguez, Nam Dang, Larry W. Kwak, Sattva S. Neelapu and Luis E. Fayad

Data supplements

Article Figures & Data

Figures

Tables

  • Table 1

    Characteristics of 78 eligible patients treated with RABVD

    CharacteristicRABVD
    Total, N78
    Sex, n (%)
        Male40 (51)
        Female38 (49)
    Median age, y (range)32 (18-72)
    Stage, n (%)
        II28 (36)
            > 8 cm with B symptoms3 (4)
            ≥ 10 cm or mediastinal ≥ 1/3 chest diameter23 (29)
             Relapsed after previous primary radiation therapy2 (3)
        III24 (31)
        IV26 (33)
    IPS, n (%)
        06 (8)
        119 (24)
        218 (23)
        318 (23)
        ≥ 417 (22)
    CD20 status, n (%)
        Positive14 (18)
        Negative56 (72)
        Unknown8 (10)
    Postchemotherapy radiation, n (%)26 (33)
  • Table 2

    Toxicity after RABVD (N = 78)

    ToxicityGrade 1, %Grade 2, %Grade 3, %Grade 4, %Total, %
    General
        Fatigue3195449
        Pain10236040
        Alopecia23190042
    Gastrointestinal
        Nausea37198064
        Vomiting22151038
        Diarrhea1390022
        Constipation13120024
    Pulmonary
        Cough1090019
        Dyspnea1091021
    Neurologic (neuropathy)2461032
    Infection683017
    Hematologic (granulocytopenia)3815833